UK markets open in 6 hours 56 minutes

Palatin Technologies, Inc. (PTN)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.9200-0.0800 (-4.00%)
At close: 04:00PM EDT
2.0000 +0.08 (+4.17%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0000
Open1.9900
Bid1.9000 x 1000
Ask2.0000 x 800
Day's range1.8500 - 2.0279
52-week range1.4300 - 5.6500
Volume320,223
Avg. volume717,014
Market cap30.982M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-2.9800
Earnings date14 May 2024 - 20 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.33
  • Insider Monkey

    10 Micro-Cap Healthcare Stocks Insiders Are Buying

    In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]

  • Zacks

    Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

    A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

  • Benzinga

    Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

    On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated